https://mugglehead.com/grail-galleri-fda-panel-briefing-documents/ Mugglehead Media en 2026-09-22T05:11:12.693Z GRAIL jumps 34% as FDA staff raise no major concerns on Galleri cancer test NASDAQ: GRAL, NYSE: ABT, GRAIL, Abbott Laboratories, Galleri, Cancer screening, FDA